The market is also propelled by the growing need for immunoassays in diagnosing microorganism-based infections and an increasing awareness of the benefits of protein degradation.
The targeted protein degradation (TPD) market is growing rapidly and is expected to continue its upward trajectory in 2024 making it a biotech trend to follow. This growth is driven by the increasing adoption of advanced technology in therapeutic methods, rising usage of technology for epichaperome inhibitors, and a growing demand for protein degradation strategies in drug discovery. The market is also propelled by the growing need for immunoassays in diagnosing microorganism-based infections and an increasing awareness of the benefits of protein degradation.